Diatech files IND for infection agent

Article

Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H,

Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H, is a technetium-99m-labeled syntheticpeptide designed to home in on infection sites where white bloodcells are elevated as the body fights infection.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Current Insights on Interoperability, Enterprise Imaging and AI Integration in Radiology
A Closer Look at the Mammo Enhance Heart Program: An Interview with Arthy Saravanan, MD
Current Perspectives on Prostate Cancer and Emerging Theranostic Agents, Part 1
© 2025 MJH Life Sciences

All rights reserved.